Stanley Erck has served on our Board since 2005. Mr. Erck served as president and chief executive officer of Novavax, Inc., from 2011, and as a director of Novavax from 2009, until his retirement in January 2023.
Mr. Erck previously served as executive chairman of Novavax from 2010 to 2011 and interim chief financial officer from 2017 to 2018. From 2000 to 2008, Mr. Erck served as president and chief executive officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG.
He previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Within the past five years, Mr. Erck served on the board of directors of BioCryst Pharmaceuticals.
Mr. Erck received a BS in economics from the University of Illinois and an MBA from the University of Chicago. During his tenure as chief executive officer of Novavax, Mr. Erck led the company from preclinical development through global commercialization with first year revenues of $2 billion.
Our Board believes Mr. Erck’s public company board experience and extensive knowledge and experience in the biotechnology industry qualify him to serve as a director.
What is Stanley C. Erck's net worth?
The estimated net worth of Stanley C. Erck is at least $629.36 thousand as of August 13th, 2025. Mr. Erck owns 398,328 shares of MaxCyte stock worth more than $629,358 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Erck may own. Learn More about Stanley C. Erck's net worth.
How do I contact Stanley C. Erck?
Has Stanley C. Erck been buying or selling shares of MaxCyte?
Stanley C. Erck has not been actively trading shares of MaxCyte during the last ninety days. Most recently, on Wednesday, August 13th, Stanley C. Erck bought 100,000 shares of MaxCyte stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $137,000.00. Following the completion of the transaction, the director now directly owns 398,328 shares of the company's stock, valued at $545,709.36. Learn More on Stanley C. Erck's trading history.
Who are MaxCyte's active insiders?
Are insiders buying or selling shares of MaxCyte?
In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 7 times. They sold a total of 29,653 shares worth more than $95,594.74. The most recent insider tranaction occured on August, 13th when CFO Douglas J Swirsky bought 50,000 shares worth more than $64,500.00. Insiders at MaxCyte own 3.3% of the company.
Learn More about insider trades at MaxCyte. Information on this page was last updated on 8/13/2025.
